Professor Jeju National University Jeju, Cheju-do, Republic of Korea
Abstract:
Background: Lymphoma is one of the most common malignant tumors in dogs. Combination chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone (CHOP) is the most effective treatment for multicentric lymphoma. Previous studies have evaluated the response of large dogs to CHOP treatment and identified prognostic factors; however, studies on small-breed dogs are lacking.
Objectives: The aim of this study was to evaluate the outcomes and prognostic factors in multicentric lymphoma small-breed dogs (weighing under 15 kg) administered the CHOP protocol. Animals: Thirty eight small-breed dogs were included.
Methods: retrospective study
Results: The responses of lymphoma dogs to CHOP treatment were assessed, and 54.3% were evaluated as being in complete remission (CR), 31.4% in partial remission (PR), and 14.3% in no remission (NR). The overall response rate was 85.7%. The mean survival time (MST) of all patients was 490.6 ± 474.5 days. MSTs for CR, PR, and NR patients were 666.9 ± 436.7, 297.2 ± 263.3, and 170.8 ± 136.0 days, respectively. Among the CR patients, MST was longer under the following conditions: age under 10 years (p = 0.011), no cardiovascular heart disease (p = 0.002), and no history of hospitalization due to side effects from chemotherapy (p = 0.031). Conclusion and clinical importance: These results might help clinicians build treatment plan of multicentric lymphoma in small-breed dogs.
